Literature DB >> 7512731

Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody.

A J Conley1, J A Kessler, L J Boots, J S Tung, B A Arnold, P M Keller, A R Shaw, E A Emini.   

Abstract

The antiviral characteristics of monoclonal antibody IAM-41-2F5 (2F5) were determined in cell culture. The antibody had been previously shown to bind a specific sequence, ELDKWA, within the external domain of the gp41 envelope glycoprotein human immunodeficiency virus type 1 (HIV-1). Selection by 2F5 of recombinant phage from an epitope library confirmed the identification of the antibody's binding determinant. The antibody was found to be capable of neutralizing a broad range of lymphoid cell culture-adapted HIV-1 variants as well as HIV-1 primary isolates. Sequence analysis of the latter showed that neutralization was related to the presence of the antibody binding site. From kinetic measurements using an epitope-containing peptide or gp41, the half-time of dissociation for 2F5 was determined to be 122 min for the peptide and 156 min for gp41. The region of gp41 expressing this sequence exhibits greater conservation among HIV-1 isolates than do the variable domains of gp120.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7512731      PMCID: PMC43574          DOI: 10.1073/pnas.91.8.3348

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding.

Authors:  U Olshevsky; E Helseth; C Furman; J Li; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

2.  Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system.

Authors:  R Karlsson; A Michaelsson; L Mattsson
Journal:  J Immunol Methods       Date:  1991-12-15       Impact factor: 2.303

3.  An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection.

Authors:  M R Posner; T Hideshima; T Cannon; M Mukherjee; K H Mayer; R A Byrn
Journal:  J Immunol       Date:  1991-06-15       Impact factor: 5.422

4.  Vertical transmission of human immunodeficiency virus (HIV) infection. Reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1.

Authors:  K E Ugen; J J Goedert; J Boyer; Y Refaeli; I Frank; W V Williams; A Willoughby; S Landesman; H Mendez; A Rubinstein
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

5.  Generation and characterization of a human monoclonal antibody that neutralizes diverse HIV-1 isolates in vitro.

Authors:  D F Lake; T Kawamura; T Tomiyama; W E Robinson; Y Matsumoto; Y Masuho; E M Hersh
Journal:  AIDS       Date:  1992-01       Impact factor: 4.177

6.  Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein.

Authors:  M Thali; C Furman; D D Ho; J Robinson; S Tilley; A Pinter; J Sodroski
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

7.  Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins.

Authors:  P A Broliden; A von Gegerfelt; P Clapham; J Rosen; E M Fenyö; B Wahren; K Broliden
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

8.  A microtiter cell-culture assay for the determination of anti-human immunodeficiency virus neutralizing antibody activity.

Authors:  G A Robertson; B M Kostek; W A Schleif; J A Lewis; E A Emini
Journal:  J Virol Methods       Date:  1988-07       Impact factor: 2.014

9.  Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus.

Authors:  M Girard; M P Kieny; A Pinter; F Barre-Sinoussi; P Nara; H Kolbe; K Kusumi; A Chaput; T Reinhart; E Muchmore
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-15       Impact factor: 11.205

10.  Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody.

Authors:  E A Emini; W A Schleif; J H Nunberg; A J Conley; Y Eda; S Tokiyoshi; S D Putney; S Matsushita; K E Cobb; C M Jett
Journal:  Nature       Date:  1992-02-20       Impact factor: 49.962

View more
  92 in total

1.  Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV.

Authors:  S Zolla-Pazner; M K Gorny; P N Nyambi; T C VanCott; A Nádas
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.

Authors:  C E Parker; L J Deterding; C Hager-Braun; J M Binley; N Schülke; H Katinger; J P Moore; K B Tomer
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 3.  Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.

Authors:  J P Moore; P W Parren; D R Burton
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

4.  Wash-free, electrochemical platform for the quantitative, multiplexed detection of specific antibodies.

Authors:  Ryan J White; Hannah M Kallewaard; Wen Hsieh; Adriana S Patterson; Jesse B Kasehagen; Kevin J Cash; Takanori Uzawa; H Tom Soh; Kevin W Plaxco
Journal:  Anal Chem       Date:  2012-01-03       Impact factor: 6.986

5.  Infection of specific dendritic cells by CCR5-tropic human immunodeficiency virus type 1 promotes cell-mediated transmission of virus resistant to broadly neutralizing antibodies.

Authors:  Lakshmanan Ganesh; Kwanyee Leung; Karin Loré; Reuven Levin; Amos Panet; Owen Schwartz; Richard A Koup; Gary J Nabel
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

6.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

Authors:  A Trkola; A B Pomales; H Yuan; B Korber; P J Maddon; G P Allaway; H Katinger; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus.

Authors:  T Muster; B Ferko; A Klima; M Purtscher; A Trkola; P Schulz; A Grassauer; O G Engelhardt; A García-Sástre; P Palese
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L.

Authors:  Ann J Hessell; Eva G Rakasz; David M Tehrani; Michael Huber; Kimberly L Weisgrau; Gary Landucci; Donald N Forthal; Wayne C Koff; Pascal Poignard; David I Watkins; Dennis R Burton
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

10.  Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles.

Authors:  Hongtao Zhang; Yujun Huang; Raja Fayad; Gregory T Spear; Liang Qiao
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.